EE05529B1 - Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil - Google Patents

Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil

Info

Publication number
EE05529B1
EE05529B1 EEP200800014A EEP200800014A EE05529B1 EE 05529 B1 EE05529 B1 EE 05529B1 EE P200800014 A EEP200800014 A EE P200800014A EE P200800014 A EEP200800014 A EE P200800014A EE 05529 B1 EE05529 B1 EE 05529B1
Authority
EE
Estonia
Prior art keywords
meldonium
pharmaceutical composition
composition based
transcriptase inhibitor
transcriptase
Prior art date
Application number
EEP200800014A
Other languages
English (en)
Estonian (et)
Inventor
Klusha Vija
Isajevs Sergejs
Pupure Jolanta
Rumaks Juris
Gordjushina Valentina
Taivans Immanuels
Kalvinsh Ivars
Original Assignee
Latvian Institute Of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05529(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Latvian Institute Of Organic Synthesis filed Critical Latvian Institute Of Organic Synthesis
Publication of EE200800014A publication Critical patent/EE200800014A/xx
Publication of EE05529B1 publication Critical patent/EE05529B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200800014A 2005-08-15 2006-08-08 Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil EE05529B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
PCT/LV2006/000005 WO2007021164A1 (en) 2005-08-15 2006-08-08 Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium

Publications (2)

Publication Number Publication Date
EE200800014A EE200800014A (et) 2008-06-16
EE05529B1 true EE05529B1 (et) 2012-04-16

Family

ID=37442067

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200800014A EE05529B1 (et) 2005-08-15 2006-08-08 Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil

Country Status (17)

Country Link
US (1) US7700576B2 (lv)
EP (1) EP1933823B1 (lv)
JP (1) JP5027809B2 (lv)
CN (1) CN101252925B (lv)
AR (1) AR066995A1 (lv)
AT (1) ATE493123T1 (lv)
DE (1) DE602006019293D1 (lv)
EE (1) EE05529B1 (lv)
ES (1) ES2361185T3 (lv)
HN (1) HN2006029085A (lv)
LT (1) LT5524B (lv)
LV (1) LV13544B (lv)
PE (1) PE20070233A1 (lv)
SV (1) SV2007002655A (lv)
UA (1) UA90162C2 (lv)
UY (1) UY29751A1 (lv)
WO (1) WO2007021164A1 (lv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021588B1 (ru) * 2009-06-25 2015-07-30 Тетра Сиа Бетаиновые соли ацетилсалициловой кислоты
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompoz&imacr;cija trimetilam&imacr;na-N-oks&imacr;da l&imacr;me&ncedil;a pazemin&amacr;&scaron;anai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997646A1 (ru) 1978-11-27 1983-02-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Кормова добавка
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1255039B (it) 1992-03-11 1995-10-13 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Also Published As

Publication number Publication date
CN101252925A (zh) 2008-08-27
LT2008003A (en) 2008-07-25
JP2009504731A (ja) 2009-02-05
LV13544B (en) 2007-05-20
UY29751A1 (es) 2007-03-30
UA90162C2 (ru) 2010-04-12
DE602006019293D1 (de) 2011-02-10
WO2007021164A1 (en) 2007-02-22
US7700576B2 (en) 2010-04-20
AR066995A1 (es) 2009-09-30
ES2361185T3 (es) 2011-06-14
HN2006029085A (es) 2007-11-16
EP1933823B1 (en) 2010-12-29
JP5027809B2 (ja) 2012-09-19
EP1933823A1 (en) 2008-06-25
ATE493123T1 (de) 2011-01-15
EE200800014A (et) 2008-06-16
SV2007002655A (es) 2007-04-12
US20090137522A1 (en) 2009-05-28
CN101252925B (zh) 2012-04-25
PE20070233A1 (es) 2007-06-08
LT5524B (lt) 2008-10-27

Similar Documents

Publication Publication Date Title
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
NO20053161D0 (no) Mikrobedrepende sammensetning.
BRPI0714539A2 (pt) &#34;formas farmacêuticas&#34;
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0614730A2 (pt) composto, composição farmacêutica, e, uso de um composto
ITPN20050014A1 (it) &#34;piedino livellatore perfezionato&#34;
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
BRPI0611025A2 (pt) composto, uso de um composto, e, composição farmacêuticamente aceitável
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0611748A2 (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
DK1963295T3 (da) 3,6-dihydro-2-oxo-6H-(1,3,4)thiazinderivater
BRPI0614412A2 (pt) composto, e, composição farmacêutica
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
EE05529B1 (et) Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil
BRPI0612270A2 (pt) composto, composição farmacêutica, e, uso de um composto
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
FR2892125B1 (fr) Composition a base d&#39;hydrofluorocarbures
BRPI0816800A2 (pt) Composto, composição farmacêutica, e, uso de um composto.

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20140808